Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed

OriGene to Acquire SDIX's Life Science Business Assets


//health-fitness.news-articles.net/content/2013/ .. acquire-sdix-s-life-science-business-assets.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


OriGene to Acquire SDIX's Life Science Business Assets -- ROCKVILLE, Md., April 8, 2013 /PRNewswire/ --

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of [ SDIX ]™ (NASDAQ: [ SDIX ]), a leading provider of biotechnology-based products and services. 

(Logo: [ http://photos.prnewswire.com/prnh/20130408/DC90285LOGO ])

"We anticipate the combination of SDIX with OriGene will enhance our ability to continue to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications both in research and diagnostics fields.  SDIX's over 20 years of antibody development and production expertise will complement OriGene's existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies such as UltraMAB™," said Wei-Wu He , Ph.D., OriGene's Chairman and Chief Executive Officer.  OriGene expects the acquisition of SDIX to:

  • Enhance the capabilities of OriGene to provide the most comprehensive immunization strategies for antibody development using full-length mammalian produced protein and genetic immunization technologies to create the highest quality monoclonal antibodies available
  • Expand antibody and IVD reagent product and services capabilities to create significant new commercial opportunities for our existing and new customers including producing UltraMAB™ for future diagnostic uses

This transaction will uniquely position OriGene as one of the leaders in antibody development and production to help our customers find the best solutions for their antibody and assay needs.  The acquisition is expected to be completed during the second quarter of 2013, subject to the approval of SDIX's shareholders and other customary closing conditions.

About OriGene Technologies

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significant improvement over traditional antibodies in antibody specificity.  UltraMAB™ antibodies are validated by OriGene's proprietary high density microarray technology for a wide variety of antibody applications. 

For more information, visit [ www.origene.com ].

SOURCE OriGene Technologies, Inc.



RELATED LINKS
[ http://www.origene.com ]

Publication Contributing Sources